Published 03-04-04
Submitted by Institute for OneWorld Health
Dr. Hale will speak as part of an esteemed panel at the Third Annual Conference on Borderless Giving entitled "Partnerships with Social Entrepreneurs to Build Social Capital." Other panel members include Pamela Hartigan, Managing Director at the Schwab Foundation for Social Entrepreneurship and Mel Young, President of the International Network of Street Papers. Sally Osberg, President and CEO of the Skoll Foundation, will moderate the session. The panel today is part of a global gathering held at Stanford University to connect philanthropic donors with one another, foundation executives, trusted intermediaries, non-governmental organizations, and social entrepreneurs. Dr. Hale was named one of 10 Outstanding Social Entrepreneurs worldwide by the Schwab Foundation last year.
"OneWorld Health seeks to stimulate all organizations to commit some part of their resources to the cure of treatable diseases in the developing world," said Dr. Hale. "Forums such as the Conference on Borderless Giving and the Social Enterprise Alliance enable us to show how a business model with a social mission can be successful. At the same time, we learn and share knowledge with other social entrepreneurs to create new ideas to engage and motivate philanthropy, industry, and academia," she said.
At the culmination of its three-day national conference in San Francisco tomorrow, the Social Enterprise Alliance will recognize OneWorld Health with a Community Achievement Award in the "New Model/Organization" category. "It is an honor to be chosen as an organization that has designed the most innovative model in the field of social enterprise," stated Moli Steinert, OneWorld Health Development Director, who will accept the award on behalf of the company. The Social Enterprise Alliance, a national organization, builds sustainable nonprofits through earned income strategies.
The Institute for OneWorld Health, a nonprofit pharmaceutical company, advances global health by developing new, affordable medicines for infectious diseases that disproportionately affect people in the developing world. OneWorld Health accomplishes this through an entrepreneurial business model in which its staff of experienced pharmaceutical scientists identifies promising drug leads and drives their development from pre-clinical studies to clinical trials through regulatory approval. The Institute for OneWorld Health, headquartered in San Francisco, is a tax-exempt 501(c)(3), U.S. corporation.